Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting

Pharmacogenetics and Genomics

Volumn 27, Issue 11, 2017, Pages 387-393

  Bousman, Chad A ^a,b   Jaksa, Philip ^a,d   Pantelis, Christos ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Department of General Practice ^*  (Australia)

^c MELBOURNE HEALTH   (Australia)

^d ACT Health   (Australia)

Author keywords

Antidepressants; Antipsychotics; Cytochrome P450; Decision making; Pharmacogenomics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYP2C19 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ALLELE; ARTICLE; CLINICAL PRACTICE; DECISION SUPPORT SYSTEM; EVALUATION STUDY; PHARMACOGENETIC TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRY; GENETICS; GENOTYPE; HUMAN; MENTAL DISEASE; META ANALYSIS; PHARMACOGENETICS; TRENDS;

ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; PSYCHIATRY;

EID: 85030833866     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000303     Document Type: Article

References (27)

1. Drew L. Pharmacogenetics: The right drug for you. Nature 2016; 537: S60-S62.
2. Hodson R. Precision medicine. Nature 2016; 537:S49.
3. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebocontrolled trials. Mol Psychiatry 2009; 14:429-447.
4. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974-981.
5. Bousman CA, Hopwood M. Commercial pharmacogenetic-based decisionsupport tools in psychiatry. Lancet Psychiatry 2016; 3:585-590.
6. Abbasi J. Getting pharmacogenomics into the clinic. JAMA 2016; 316:1533-1535.
7. de Leon J. Pharmacogenetic tests in psychiatry: from fear to failure to hype. J Clin Psychopharmacol 2016; 36:299-304.
8. Walden LM, Brandl EJ, Changasi A, Sturgess JE, Soibel A, Notario JF, et al. Physicians' opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res 2015; 229:913-918.
9. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91:450-458.
10. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J 2012; 12:197-204.
11. McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, et al. Patient perceptions of care as influenced by a large institutional pharmacogenomic implementation program. Clin Pharmacol Ther 2016. [Epub ahead of print].
12. Jones PM. FDA regulation of LDTs: an update. Med Lab Obs 2015; 47:18-19.
13. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry 2015; 16:76-95.
14. Drozda K, Muller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 2014; 34:166-184.
15. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 2016; 19:215-223.
16. Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther 2016; 99:172-185.
17. Padmanabhan S. Handbook of pharmacogenomics and stratified medicines. London: Academic Press; 2014.
18. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93:402-408.
19. Hicks JK, Bishop JR, Sangkuhl K, Müller D, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98:127-134.
20. Sim SC, Ingelman-Sundberg M. Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. Methods Mol Biol 2013; 987:251-259.
21. Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry 2017; 78:720-729.
22. Berm EJ, Looff M, Wilffert B, Boersma C, Annemans L, Vegter S, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: A systematic review. second update of the literature. PLoS One 2016; 11:e0146262.
23. Pratt VM, Everts RE, Aggarwal P, Beyer BN, Broeckel U, Epstein-Baak R, et al. Characterization of 137 genomic DNA reference materials for 28 pharmacogenetic genes: A GeT-RM collaborative project. J Mol Diagn 2016; 18:109-123.
24. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: A peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010; 4:278-281.
25. Poolsup N, Li W, Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25:197-220.
26. Ng CH, Schweitzer I, Norman T, Easteal S. The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust N Z J Psychiatry 2004; 38:483-489.
27. Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado A, de Andrés A, et al. Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. Pharmacogenomics J 2016; 16:113-123.